<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs used for the treatment of hypertensive emergencies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs used for the treatment of hypertensive emergencies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drugs used for the treatment of hypertensive emergencies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Varon, MD, FACP, FCCP, FCCM, FRSM</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William B White, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A hypertensive emergency is present when severe hypertension is associated with acute end-organ damage. Examples include hypertensive encephalopathy, acute pulmonary edema, aortic dissection, and rebound after abrupt withdrawal of antihypertensive medications. Immediate but careful reduction in blood pressure is often indicated in these settings. However, an excessive hypotensive response is potentially dangerous, possibly leading to ischemic complications such as stroke, myocardial infarction, or blindness. Thus, in patients who are severely hypertensive but asymptomatic, slower reductions in blood pressure may be achieved with oral agents. (See <a class="local">'Oral drugs'</a> below.)</p><p>The drugs that are used for the treatment of hypertensive emergencies are presented in this topic. The evaluation of patients with severe hypertension and the blood pressure goals in patients with hypertensive emergencies are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PARENTERAL DRUGS</span><span class="headingEndMark"> — </span>A variety of parenteral and oral antihypertensive drugs are available for use in these patients  (<a class="graphic graphic_table graphicRef64066" href="/z/d/graphic/64066.html" rel="external">table 1</a>) [<a href="#rid1">1-7</a>]. Few studies have compared these agents with one another, and all are tolerated reasonably well [<a href="#rid8">8,9</a>]. Thus, the drug of choice is often dictated by the type of hypertensive emergency and the local hospital formulary. (See  <a class="medical medical_review" href="/z/d/html/3833.html" rel="external">"Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults"</a>.)</p><p class="headingAnchor" id="H882605687"><span class="h2">Nitrates</span><span class="headingEndMark"> — </span>Nitrovasodilators such as <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> and <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> provide nitric oxide that induces vasodilatation (of both arterioles and veins) via generation of cyclic GMP, which then activates calcium-sensitive potassium channels in the cell membrane [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3"><span class="h3">Nitroprusside</span><span class="headingEndMark"> — </span>Sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, when administered by intravenous infusion, begins to act within one minute or less, and once discontinued, its effects disappear within 10 minutes or less. Frequent monitoring is required since this drug can produce a sudden and drastic drop in blood pressure.</p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> is 0.25 to 0.5 mcg/kg per minute. This can be increased as necessary to a maximum dose of 8 to 10 mcg/kg per minute, although use of these higher doses should generally be avoided or limited to a maximum duration of 10 minutes [<a href="#rid11">11</a>].</p><p>Toxicities and limitations of <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">Nitroprusside</a> is metabolized to cyanide, possibly leading to the development of cyanide (or, rarely, thiocyanate) toxicity that may be fatal [<a href="#rid11">11</a>]. This problem, which can manifest in as little as four hours, presents with altered mental status and lactic acidosis. Risk factors for nitroprusside-induced cyanide poisoning include a prolonged treatment period (&gt;24 to 48 hours), underlying kidney function impairment, and the use of doses that exceed the capacity of the body to detoxify cyanide (ie, more than 2 mcg/kg per minute). The risk of toxicity can be minimized by using the lowest possible dose, avoiding prolonged use (ie, no more than two or three days), and by careful patient monitoring (with special attention to unexplained acidemia or decreasing serum bicarbonate concentrations).</p><p></p><p class="bulletIndent1">In addition, doses of 10 mcg/kg per minute should never be given for more than 10 minutes. An infusion of <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">sodium thiosulfate</a> can be used in affected patients to provide a sulfur donor to detoxify cyanide into thiocyanate [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">Nitroprusside</a> can result in dose-related declines in coronary, kidney, and cerebral perfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">Nitroprusside</a> should <strong>not</strong> be given to pregnant women, patients with Leber optic atrophy, or patients with tobacco amblyopia. In addition, nitroprusside should be avoided, if possible, in patients with impaired kidney function. (See <a class="local">'Fenoldopam'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The high cost of nitroprusside may limit its availability in some settings. (See  <a class="drug drug_general" href="/z/d/drug information/9707.html" rel="external">"Nitroprusside: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Nitroglycerin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">Nitroglycerin</a> is also administered by intravenous infusion and is similar in action and pharmacokinetics to <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> except that it produces relatively greater venodilation than arteriolar dilation. It has less antihypertensive efficacy compared with other drugs used to treat hypertensive emergencies, and its effects on blood pressure are variable from person to person and, potentially, from minute to minute. However, it may be useful in patients with symptomatic coronary disease and in those with hypertension following coronary bypass. Prolonged infusions are generally avoided to prevent tachyphylaxis. (See  <a class="medical medical_review" href="/z/d/html/64.html" rel="external">"Nitrates in the management of acute coronary syndrome", section on 'Nitrate tolerance'</a>.)</p><p>The initial dose of <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> is 5 mcg/min, which can be increased as necessary to a maximum of 100 mcg/min. The onset of action is 2 to 5 minutes, while the duration of action is 5 to 10 minutes. Headache (due to direct vasodilation) and tachycardia (resulting from reflex sympathetic activation) are the primary adverse effects. Cyanide accumulation does not occur. Methemoglobinemia has been reported in patients receiving this agent for more than 24 hours [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Calcium channel blockers</span></p><p class="headingAnchor" id="H6"><span class="h3">Clevidipine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">Clevidipine</a> is an ultra-short-acting dihydropyridine calcium channel blocker that is approved for intravenous use to treat severe hypertension. The drug is hydrolyzed by serum esterases and has a serum elimination half-life of 5 to 15 minutes. It reduces blood pressure without affecting cardiac filling pressures but can cause reflex tachycardia [<a href="#rid1">1,12</a>]. Clevidipine is contraindicated in patients with severe aortic stenosis (because it increases the risk of severe hypotension), disordered lipid metabolism (because it is administered in a lipid-laden emulsion), or known allergies to soy or eggs (because these are used to produce the emulsion). It has not been compared with other short-acting drugs, such as <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> and <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> in hypertensive emergencies, but it was as or more effective than nitroglycerin, nitroprusside, and <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a> in acutely hypertensive patients during and after cardiac surgery [<a href="#rid13">13</a>]. The initial dose is 1 mg/hour, which can be increased as necessary to a maximum of 21 mg/hour.</p><p class="headingAnchor" id="H7"><span class="h3">Nicardipine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">Nicardipine</a> is a dihydropyridine calcium channel blocker (like <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>) that can be given as an intravenous infusion. The initial dose is 5 mg/hour and can be increased to a maximum of 15 mg/hour. Nicardipine has a better safety profile and a similar antihypertensive effect when compared with <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> [<a href="#rid14">14</a>]. The major limitations are a longer onset of action, which precludes rapid titration, and a longer serum elimination half-life (three to six hours).</p><p class="headingAnchor" id="H352188424"><span class="h2">Dopamine-1 agonist</span></p><p class="headingAnchor" id="H8"><span class="h3">Fenoldopam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">Fenoldopam</a> is a peripheral dopamine-1 receptor agonist which, unlike other parenteral antihypertensive agents, maintains or increases kidney perfusion while it lowers blood pressure [<a href="#rid15">15</a>]. Fenoldopam may be particularly beneficial in patients with kidney function impairment and, compared with <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, may increase glomerular filtration rate, urine output, and sodium excretion [<a href="#rid16">16,17</a>]. After starting at 0.1 mcg/kg per minute, the dose can be titrated at 15-minute intervals to 1.6 mcg/kg per minute, depending upon the blood pressure response. Some experts have used doses as high as 2.0 mcg/kg per minute or higher without inducing toxicity.</p><p><a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">Fenoldopam</a> should be used cautiously or not at all in patients with glaucoma [<a href="#rid15">15</a>]. In addition, because this agent is premixed in a solution containing sodium metabisulfite, caution is recommended for patients with sulfite sensitivity.</p><p class="headingAnchor" id="H352188453"><span class="h2">Adrenergic-blocking agents</span></p><p class="headingAnchor" id="H9"><span class="h3">Labetalol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> is a combined beta-adrenergic and alpha-adrenergic blocker. Its rapid onset of action (five minutes or less) makes it a useful intravenous medication for the treatment of hypertensive emergencies. However, one trial found that labetalol has less antihypertensive efficacy as compared with <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a> [<a href="#rid18">18</a>].</p><p><a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> is safe in patients with active coronary disease since it does not increase heart rate. However, labetalol should be avoided in patients with asthma, chronic obstructive lung disease, heart failure, bradycardia, or greater than first-degree heart block. In addition, labetalol should not be used without prior adequate alpha blockade in patients with hyperadrenergic states, such as pheochromocytoma or cocaine or methamphetamine overdose, since unopposed, inadequately blocked alpha-adrenergic activity can increase blood pressure if beta blockade is not complete. (See  <a class="medical medical_review" href="/z/d/html/303.html" rel="external">"Cocaine: Acute intoxication"</a>.)</p><p><a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> can be given as a series of intravenous bolus injections or as a constant-dose infusion. The bolus dose is 20 mg initially, followed by 20 to 80 mg every 10 minutes to a total dose of 300 mg. The infusion rate is 0.5 to 2 mg/min. Higher total doses and higher infusion rates are sometimes used, particularly in patients who are overweight or who have obesity.</p><p class="headingAnchor" id="H10"><span class="h3">Esmolol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">Esmolol</a>, a relatively cardioselective beta blocker, is rapidly metabolized by blood esterases. Its effects begin almost immediately, and it has both a short half-life (approximately 9 minutes) and a short total duration of action (approximately 30 minutes), permitting rapid titration. Esmolol is often used during anesthesia to prevent postintubation hemodynamic perturbations.</p><p class="headingAnchor" id="H352188499"><span class="h2">Other agents</span></p><p class="headingAnchor" id="H11"><span class="h3">Hydralazine</span><span class="headingEndMark"> — </span>Although <strong>not</strong> a preferred agent for hypertensive emergencies, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> is a direct arteriolar vasodilator with little or no effect on the venous circulation. Thus, precautions are needed in patients with underlying coronary disease or aortic dissection, and a beta blocker should be given concurrently to minimize reflex sympathetic stimulation. The hypotensive response to hydralazine is less predictable than that seen with other parenteral agents. Although intravenous hydralazine is often given to hospitalized patients when blood pressures exceeding arbitrary thresholds, there is little evidence that this practice improves outcomes, and it can be associated with hypotension [<a href="#rid19">19</a>]. The most evidence-based use of parenteral hydralazine is primarily limited to pregnant women, although a reduction in the utero-placental blood flow has been reported in such patients. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>.)</p><p><a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">Hydralazine</a> can be given as an intravenous bolus. The initial dose is 10 mg, with the maximum dose being 20 mg. The fall in blood pressure can be sudden and begins within 10 to 30 minutes and lasts two to four hours.</p><p class="headingAnchor" id="H12"><span class="h3">Enalaprilat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17094" href="/z/d/drug information/17094.html" rel="external">Enalaprilat</a> is the intravenously active, des-ethyl ester of the angiotensin-converting enzyme (ACE) inhibitor, <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a>. The hypotensive response to enalaprilat is unpredictable and depends upon the plasma volume and plasma renin activity in individual patients with a hypertensive emergency [<a href="#rid20">20</a>]. Typically, hypovolemic patients with a high plasma renin activity are most likely to have an excessive hypotensive response. In addition, ACE inhibitors are contraindicated in pregnancy, severe renal artery stenosis with kidney ischemia, and severe hyperkalemia. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p>The usual initial dose is 1.25 mg. As much as 5 mg may be given every six hours as necessary [<a href="#rid20">20</a>]. The onset of action begins in 15 minutes, but the peak effect may not be seen for four hours. The duration of action ranges from 12 to 24 hours.</p><p class="headingAnchor" id="H13"><span class="h3">Phentolamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">Phentolamine</a> is a nonselective alpha-adrenergic blocker, the use of which is limited to the treatment of severe hypertension due to increased catecholamine activity. Examples include pheochromocytoma or tyramine ingestion in a patient being treated with a monoamine oxidase inhibitor. However, it is not more effective than other alpha-adrenergic blockers, and its availability may be limited in many centers. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a> and  <a class="medical medical_review" href="/z/d/html/142.html" rel="external">"Treatment of pheochromocytoma in adults"</a>.)</p><p><a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">Phentolamine</a> is given as an intravenous bolus. The usual dose is 5 to 15 mg every 5 to 15 minutes as necessary. Patients receiving this agent who do not require intravenous therapy can be converted to oral <a class="drug drug_general" data-topicid="9764" href="/z/d/drug information/9764.html" rel="external">phenoxybenzamine</a>.</p><p class="headingAnchor" id="H14"><span class="h1">ORAL DRUGS</span><span class="headingEndMark"> — </span>Oral antihypertensive agents usually lower the blood pressure more slowly than parenteral drugs. Thus, they are primarily used when parenteral agents are not available or when there is severe hypertension without serious acute end-organ damage. (See  <a class="medical medical_review" href="/z/d/html/3830.html" rel="external">"Management of severe asymptomatic hypertension (hypertensive urgencies) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3833.html" rel="external">"Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults"</a>.)</p><p class="headingAnchor" id="H601532368"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H158820980"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17188.html" rel="external">"Patient education: High blood pressure emergencies (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertensive emergency</strong> – A hypertensive emergency is defined as severe hypertension that is associated with acute end-organ damage. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Immediate but careful reduction in blood pressure is indicated in hypertensive emergencies; an excessive hypotensive response may lead to ischemic complications. A variety of parenteral and oral antihypertensive drugs are available for use in these patients  (<a class="graphic graphic_table graphicRef64066" href="/z/d/graphic/64066.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Parenteral drugs'</a> above.)</p><p></p><p class="bulletIndent1">Parenteral drugs include <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a>, <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">clevidipine</a>, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="17094" href="/z/d/drug information/17094.html" rel="external">enalaprilat</a>, and <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">phentolamine</a>. (See <a class="local">'Parenteral drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe asymptomatic hypertension</strong> – Among patients who are severely hypertensive but asymptomatic, slower reductions in blood pressure may be provided with oral agents. (See <a class="local">'Oral drugs'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Padilla Ramos A, Varon J. Current and newer agents for hypertensive emergencies. Curr Hypertens Rep 2014; 16:450.</a></li><li><a class="nounderline abstract_t">Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.</a></li><li><a class="nounderline abstract_t">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.</a></li><li><a class="nounderline abstract_t">Rossi GP, Rossitto G, Maifredini C, et al. Modern Management of Hypertensive Emergencies. High Blood Press Cardiovasc Prev 2022; 29:33.</a></li><li><a class="nounderline abstract_t">Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002; 17:937.</a></li><li><a class="nounderline abstract_t">Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 2008; 22:596.</a></li><li><a class="nounderline abstract_t">Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs 2008; 68:283.</a></li><li><a class="nounderline abstract_t">Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 1998; 19:99.</a></li><li><a class="nounderline abstract_t">Peacock F, Amin A, Granger CB, et al. Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med 2011; 29:855.</a></li><li><a class="nounderline abstract_t">Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994; 91:7583.</a></li><li><a class="nounderline abstract_t">Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984; 9:239.</a></li><li><a class="nounderline abstract_t">Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs 2014; 74:1947.</a></li><li><a class="nounderline abstract_t">Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008; 107:1110.</a></li><li><a class="nounderline abstract_t">Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens 1994; 7:623.</a></li><li><a class="nounderline abstract_t">Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345:1548.</a></li><li><a class="nounderline abstract_t">White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 1989; 149:870.</a></li><li><a class="nounderline abstract_t">Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993; 95:161.</a></li><li><a class="nounderline abstract_t">Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 2011; 15:R157.</a></li><li><a class="nounderline abstract_t">Campbell P, Baker WL, Bendel SD, White WB. Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified. J Am Soc Hypertens 2011; 5:473.</a></li><li><a class="nounderline abstract_t">Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995; 155:2217.</a></li></ol></div><div id="topicVersionRevision">Topic 3840 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24863753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current and newer agents for hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972386" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817082" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34813055" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Modern Management of Hypertensive Emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18418399" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257607" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of acute severe hypertension: Current and newer agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704248" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative tolerability profile of hypertensive crisis treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20825913" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypertensive heart failure: patient characteristics, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7519783" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375932" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25312594" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806012" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7946164" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794223" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565105" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707983" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890447" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7487244" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
